Pathophysiological Models of Hypersomnolence Associated With Depression

Up to 25% of patients with depression experience hypersomnolence (e.g., excessive daytime sleepiness, hypersomnia, and/or sleep inertia), which is associated with treatment resistance, overall poorer outcomes, and safety concerns while driving. Hypersomnolence can result from various sleep/neurologi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological psychiatry global open science 2025-03, Vol.5 (2), p.100445, Article 100445
Hauptverfasser: Moderie, Christophe, Boivin, Diane B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Up to 25% of patients with depression experience hypersomnolence (e.g., excessive daytime sleepiness, hypersomnia, and/or sleep inertia), which is associated with treatment resistance, overall poorer outcomes, and safety concerns while driving. Hypersomnolence can result from various sleep/neurological disorders or side effects from medication but is often medically unexplained in depression. In this review, we aimed to summarize the different pathophysiological models of hypersomnolence in depression to discuss their impact on nosology and to foster the development of better tailored diagnostics and treatments. We identified several potential mechanisms underlying hypersomnolence including a daytime hypoactivity of dopaminergic and noradrenergic systems, nighttime GABA (gamma-aminobutyric acid) hypoactivation, hypoperfusion, and hypoconnectivity in the medial prefrontal cortex, as well as a longer circadian period and light hyposensitivity. In some patients with depression, nighttime hyperarousal can fragment sleep and result in a complaint of excessive daytime sleepiness, thus mimicking hypersomnolence. Others might adopt maladaptive behaviors such as spending excessive time in bed, a term coined clinophilia. Objective markers of hypersomnolence, such as ambulatory ad libitum polysomnography may facilitate distinguishing between conditions that mimic hypersomnolence. Our review identified several clinical targets for hypersomnolence in depression. Low-sodium oxybate, which is approved for idiopathic hypersomnia, needs additional study in patients with depression. Neuromodulation that targets prefrontal cortex anomalies should be systematically explored, while tailored light therapy protocols may mitigate light hyposensitivity. Additionally, cognitive behavioral therapy for hypersomnolence is being developed as a nonpharmacological adjunct to these treatments. Many people with depression experience hypersomnolence, which encompasses excessive daytime sleepiness and prolonged sleep duration. Hypersomnolence is associated with safety issues, such as driving concerns, and makes depression more difficult to treat. The causes of hypersomnolence in depression are unknown. In this review of the literature, we synthesize potential causes, including reduced daytime activity in brain systems that regulate alertness, nighttime sleep disruptions, altered circadian rhythms, and behaviors like spending extended time in bed. Understanding these mechanisms may support th
ISSN:2667-1743
2667-1743
DOI:10.1016/j.bpsgos.2024.100445